A 24-h helpline for access to expert management advice for food allergy-related anaphylaxis in children: protocol for a pragmatic randomised controlled trial

Maeve M Kelleher,1 Jonathan O’B Hourihane,1 Audrey DunnGalvin,1 Claire Cullinane,1 John Fitzsimons,2 Aziz Sheikh3

ABSTRACT

Objectives: Anaphylaxis is an important, potentially life-threatening paediatric emergency. It is responsible for considerable morbidity and, in some cases, death. Poor outcomes may be associated with an inability to differentiate between milder and potentially more severe reactions and an associated reluctance to administer self-injectable adrenaline. This study aims to assess the effectiveness of a 24-h telephone access to specialist paediatric allergy expert advice in improving the quality of life of children and their families with potentially life-threatening food allergy (ie, anaphylaxis) compared with usual clinical care.

Methods and analysis: Children aged less than 16 years with food allergy and who carry an adrenaline autoinjector will be recruited from the Paediatric Allergy Clinic at Cork University Hospital, Ireland and baseline disease-specific quality of life will be ascertained using the validated Food Allergy Quality of Life Questionnaire (FAQLQ). Participants will be randomised for a period of 6 months to the 24-h telephone specialist support line or usual care. The primary outcome measure of interest is a change in FAQLQ scores, which will be assessed at 0, 1 and 6 months postrandomisation. Analysis will be on an intention-to-treat basis using a 2×3 repeated measures within-between analysis of variance. Although lacking power, we will in addition assess the impact of the innovative intervention and the rigorous randomised controlled trial design being employed.

Strengths and limitations of this study

The main strengths of the study include the fact that this is one of the world’s first clinical trials of the management of people with anaphylaxis, the innovative intervention and the rigorous randomised controlled trial design being employed.

The main limitations are that we will not be adequately powered to assess the impact of the intervention on the hard clinical outcomes of hospitalisation or mortality.

INTRODUCTION

Anaphylaxis is an important, potentially life-threatening paediatric emergency. Food is responsible for the majority of anaphylaxis cases in the paediatric population. Egg, milk, peanuts and tree nuts are the most common food allergens in the preschool population; peanut and tree nuts are the most common allergen triggers in older children. There is a wide spectrum of allergic reactions to these allergens ranging from minor urticarial reactions to anaphylaxis, with the associated risk of fatality.

Anaphylaxis is managed via a two-pronged approach: first lifestyle modification to avoid the allergen and second the acute management of the anaphylactic event itself.2–4 Those children who have had anaphylaxis, or who are judged to be at high risk of anaphylaxis, are
prescribed adrenaline (epinephrine) autoinjectors. These are to be carried on their person, or by their carers, at all times in the case of accidental exposure to the allergen(s) in question. This is important as, although uncommon with an estimated incidence of one episode per 10 000 children per year, most accidental exposures and subsequent reactions tend to occur in community settings and because of the typically rapid onset and progression of reactions, most young people and their families do not have immediate access to medical support when this is most required.

Despite being prescribed an adrenaline autoinjector and being shown the correct method of administration, many young people and/or parents still often report being unsure when to administer this treatment. They often worry whether the reaction is severe enough to warrant an injection of adrenaline or whether their child may come to harm if given unnecessary treatment. There is evidence that there is often a delay in administering the prescribed medication in an emergency. This delay in administering adrenaline may lead to increased morbidity and also increases the risk of fatality. Allergy services therefore often encourage children and families/carers to use their autoinjectors if there is any doubt regarding the severity of the allergic reaction. Given the risk of further reactions and the above-described concerns about when to administer emergency treatment, it is perhaps unsurprising that studies have found that food allergy can have a detrimental impact both on the children themselves and also on family quality of life. There is, however, as yet no clear evidence on how to improve clinical and/or psychological outcomes in this population.

In the light of the above factors, we hypothesise that first, uncertainty about the likely severity of their child’s reaction (ranging from no reaction to mild to life-threatening) on accidental re-exposure to the allergenic food in question and second, what a patient or carer must do if a reaction occurs, both contribute significantly to parental/child anxiety. We further hypothesise that this uncertainty could be ameliorated by real-time expert clinical guidance and support.

We propose therefore to test the effectiveness of giving parents and carers of children and teenagers with known food allergy, who are medically considered to be at sufficient risk of anaphylaxis that they have been prescribed and trained in the use of adrenaline autoinjectors, 24-h telephone access (intervention arm) or office-hour access (routine care arm) to expert advice from the clinical allergy service. We will advise parents/carers/teen patients randomised to the intervention arm to ring this clinician-staffed advice line if they or their child has an allergic reaction and they are unsure as to how to manage it. We postulate that the availability of this service will improve disease-specific quality of life compared with families randomised to the routine care arm who do not have this 24-h access. We also suspect that the allergic reactions that parents or families contact the allergy team about will be better managed as a result of the advice given. There is currently no service such as this available in Ireland or indeed worldwide. This is, as far as we are aware, the first ever randomised clinical trial of patient care in the field of anaphylaxis.

**AIMS AND OBJECTIVES**

**Aims**

We seek to assess the effectiveness of 24-h telephone access to specialist paediatric allergy expert advice in improving the quality of life of children and their families with potentially life-threatening food allergy (ie, anaphylaxis) compared with usual clinical care.

**Main objective**

To compare the difference in food allergy related quality of life between the 24-h telephone access and usual care at 1 and 6 months postrandomisation.

**Secondary objectives**

1. To compare the number and clinical severity of incidents of suspected/confirmed allergic reaction in both groups.
2. To compare clinical and health service use outcomes in both groups.

**METHODS AND ANALYSIS**

**Design**

We will undertake a pragmatic two-arm parallel group randomised controlled trial.

**Recruitment and consent**

All families with food allergic children seen in the paediatric allergy outpatient clinic at Cork University Hospital will be informed about the study and invited to participate. A baseline-validated Food Allergy-specific Quality-of-Life questionnaire (FAQL) will be completed by interested family members in relation to each child recruited. This FAQL questionnaire will be sent by post to each family, with a stamp-addressed envelope.

Recruitment of families of children with food allergy who carry an adrenaline autoinjector will occur in the paediatric allergy outpatient clinic of Cork University Hospital, which is the main centre for specialist paediatric allergy service provision across Ireland. Notices with information about the study will be placed around the out-patient waiting rooms. A phone number with a 24-h answering service will be advertised for families wishing to obtain further information about the trial. Potentially suitable patients will also be identified from the weekly clinic preview team meetings.

All potentially interested parents will be given further information about the study, and any questions they may have will be answered. Children will, where appropriate on the basis of their age and understanding, also be involved in this discussion. Written informed consent will be obtained from all parents/guardians wishing to take part.
24-Hour access to expert anaphylaxis management advice for food allergic children

in the trial. Those over the age of 8 years will also be asked to sign an assent form in the presence of their parents.

Eligibility
Families of children satisfying the inclusion and exclusion criteria detailed below will be eligible to participate in the trial.

Inclusion criteria
1. Less than 16 years of age
2. Food allergy.
3. Previously prescribed an adrenaline autoinjector.
4. Carers and, where appropriate, children trained by the clinical service how to use the prescribed adrenaline autoinjector.
5. First eligible food allergic child in a family with more than one eligible child.

Exclusion criteria
1. Awaiting food challenge and likely to undergo this challenge during the trial period.
2. Experiencing another major life stressor during timeline of trial, for example, changing school.
3. Second or subsequent eligible child in families with more than one already recruited child.

Baseline assessment
All study participants will, as noted above, fill out FAQL questionnaires prior to randomisation. Parents will complete the FAQL parent form (FAQL-PF) as a proxy for their young children in those less than 13 years. Children age 8–13 years will complete their own validated FAQL child form (FAQL-CF) and teenagers will fill in the FAQL teen form (FAQL-TF).

Randomisation
Randomisation will be undertaken only once all participants have been recruited, thereby minimising the risk of any selection biases (that is, by maintaining allocation concealment). When all baseline questionnaires are collected, the family will then be centrally randomised by the be independently trial statistician, centrally randomised in a 1:1 ratio, into the intervention (I) or usual (U) care arms. All recruited families will thus simultaneously be allocated to the (I) or (U) arms, this marking the onset of the trial period.

Intervention and control
The (I) group will be given a direct access mobile phone number to ring in the event of a suspected serious allergic reaction. This will be given on a credit-card-sized document for ease of access in the event of an emergency. The briefing of this emergency 24-h helpline will be shared between experienced members of the paediatric allergy team. In the event of a suspected serious allergic reaction, the patient or his/her parent or carer will be able to ring the on-call trial clinician for advice. Trial staff will have a standard incident report form (appendix 1) to keep record of on-call encounters. It is to be filled out as soon as is practical after the phone-call consultation. Their advice will be tailored according to clinical need, but will include instructions that there is either: (1) no need for emergency treatment; (2) give antihistamines by mouth and observe or (3) use the adrenaline autoinjector and call an ambulance. The responding staff member will keep a record of all such encounters and the advice given. Consistency of advice given is ensured by each staff member giving out previously agreed, standardised instructions (appendix 1) and by a teleconference to be had between all personnel, following all incidents where advice is given on the 24-h helpline, to discuss the incident and ensure that the standardised advice was given.

Those allocated to the U care (control) arm will receive standard care, with the option of contacting one or more of the following: the Cork University Hospital Paediatric Allergy team during working hours (Monday–Friday 8:00–17:00), emergency/ambulance services, their own registered general practitioner, out-of-hours primary care providers or their nearest hospital emergency departments.

The duration of trial period will be 6 months from the point of randomisation.

Outcome measures
Primary
All study participants will complete the age-appropriate (discussed above) validated FAQL at 1 and 6 months post randomisation; specifically, any change from baseline between intervention and control groups at the 1-month and 6-month assessment points. The FAQL-Q-PF, FAQL-Q-CF and FAQL-Q-TF are age appropriate parent-administered, child self-administered and teen self-administered questionnaires that measure the impact of food allergy on health-related quality of life (HRQL) of children of age 0–18 years. They were developed and validated under the auspices of EuroPrevall, a European Commission-funded project with over 60 partners (www.europrevall.org). We have previously demonstrated good cross-sectional and longitudinal reliability and validity in European and US samples. The questionnaire items are scored on a seven-point likert scale ranging from 0 (no impact on HRQL) to 6 (extreme impact on HRQL). The measures have three subscales assessing general emotional impact; food anxiety; and social and dietary limitations. The total score is calculated as the mean of these three subscales.14–17

Secondary
Participants in both groups will also be asked to record any possible allergic reactions that may have occurred, which were self-managed and/or required medical advice or attention other than provided through the trial helpline. They will be provided with a standardised form to record this information on (appendix 2). We will record the clinical details of every reported event to
Statistical considerations

**Analysis**

We will assess the statistical significance and relative magnitude of changes over three time-points, that is, at baseline (T0), 1 month (T1) and 6 months (T2) post-randomisation, on the FAQLQ scores for both the (I) and (U) care groups using a repeated measures 2×3 multivariate design. That is, the same case in either experimental or control group (group factor), will complete the questionnaires at three time-points (time factor). The effect of the factors ‘time’ and ‘group’ on the total score, and the interaction of these two factors, will be analysed using a two-way within–between groups analysis of variance (ANOVA). The interaction will address the question: ‘Are the time profiles in terms of FAQL total scores of the two groups (experimental/control) significantly different?’ If improvement over time is determined, a paired sample t test will be used to ascertain at which time-point(s) the difference can be detected. Secondary outcomes will be included in univariate and multivariate models as independent and dependent variables and controls.

Independent t tests will be used to determine if there are differences in magnitude of improvement in FAQL scores for (I) vs (U) groups. The Bonferroni correction method will be used to adjust for multiple comparisons.

We will calculate the responsiveness index (mean change score/SD of change score), using Cohen’s change index benchmarks; 0.2–0.4 (small), 0.5–0.7 (moderate) and 0.81 (large).

We will assess the reliability of the change score by computing the intraclass coefficients of change in the FAQLQ. The minimal important difference (MID) will be determined, a paired sample t test will be used to ascertain at which time-point(s) the difference can be detected. Secondary outcomes will be included in univariate and multivariate models as independent and dependent variables and controls.

Independent t tests will be used to determine if there are differences in magnitude of improvement in FAQL scores for (I) vs (U) groups. The Bonferroni correction method will be used to adjust for multiple comparisons.

We will calculate the responsiveness index (mean change score/SD of change score), using Cohen’s change index benchmarks; 0.2–0.4 (small), 0.5–0.7 (moderate) and 0.81 (large).

We will assess the reliability of the change score by computing the intraclass coefficients of change in the FAQLQ. The minimal important difference (MID) will also be calculated. Because the validity of a retrospective assessment of change has been questioned, we will determine the MID by computing the SE of measurement (sp(1−r), using baseline FAQLQ scores as an ‘anchor’.

Missing data will be dealt with by the Multiple Imputation method, which is suitable for ANOVA and uses an imputation method with error built in.

Analysis will be on an intention-to-treat basis by the trial statistician who will be blinded to allocation. There are no interim analyses planned.

**Power**

We will utilise a within/between repeated measures analysis of variance. An a priori total sample size required × power (1-β err prob), for a repeated measures within-between ANOVA analysis is 16 in each group (intervention/control) to yield a statistically significant result at >90% power with a 0.5 effect level. ‘Within’ refers to expected differences between three time periods (T0, T1 and T2) and ‘between’ refers to expected differences between the intervention and control groups (figure 1).

Figure 1  A priori total sample size required×power (1-β err prob), for a repeated measures within-between analysis of variance.

**F tests:** ANOVA: repeated measures, within-between interaction

**Analysis:** A priori: compute required sample size

**Input:**
- Effect size f=0.5
- α err prob=0.05
- Power (1-β err prob)=0.95
- Number of groups=2
- Repetitions=3
- Corr among rep measures=0.4
- Nonsphericity correction r=1

**Output:**
- Non-centrality parameter λ=20.000000
- Critical F=3.340386
- Numerator df=2.000000
- Denominator df=28.000000
- Group sample size=16
- Actual power=0.973792 with an anticipated drop-out rate of 20%, we therefore plan to recruit a total of 40 families.

**ETHICS AND DISSEMINATION**

Ethical approval has been obtained by the Clinical Research Ethics Committee of the Cork Teaching Hospitals (30 May 2011). All patients are aware that their participation is voluntary and they may withdraw from study at any time.

The principal investigator (PI) for the trial is Jonathan Hourihane and he will lead the Trial Management Group and he is responsible for the overall governance and running of this trial. Other members of the Trial Management Group are: Maeve Kelleher, John Fitzsimons, Audrey DunnGalvin, Claire Cullinan and Aziz Sheikh, and they will support the PI in delivering this trial. Audrey DunnGalvin is the trial statistician.

We plan to report our findings at major national and international scientific conferences. We also plan to
publish our findings in the peer-reviewed literature. We anticipate being in a position to report on findings in early 2013.

Acknowledgements We are very grateful to the children and their families who have agreed to participate in this trial.

Contributions J'O'BH, AS and ADG conceived the idea for this trial, and this was then further developed in association with MK and ADG. MK led the drafting of this manuscript, which was critically commented on by all coauthors.

Competing interests None.

Ethics approval Clinical Research Ethics Committee of the Cork Teaching Hospitals.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


APPENDIX 1

INCIDENT REPORT FORM

<table>
<thead>
<tr>
<th>Patient name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff member name</td>
<td></td>
</tr>
<tr>
<td>Caller mother/father/patient/other</td>
<td>(Please specify)</td>
</tr>
<tr>
<td>Time of call (24 h)</td>
<td></td>
</tr>
<tr>
<td>Patient location</td>
<td></td>
</tr>
<tr>
<td>Food suspected</td>
<td></td>
</tr>
<tr>
<td>How much eaten?</td>
<td></td>
</tr>
<tr>
<td>Time since ingestion</td>
<td></td>
</tr>
<tr>
<td>Asthma y/n</td>
<td></td>
</tr>
</tbody>
</table>

Current condition

Rash only
Rash and swelling
Cough/hoarseness
Wheeze
Dizzy/collapse
Outcome (to be completed by study team in Cork, as soon as possible next working day)

Advice to be given
Give antihistamine, do not use anapen yet
Use anapen, call ambulance, go to hospital
Use anapen, call ambulance, go to hospital
Use anapen, call ambulance, go to hospital
### Anaphylaxis 24-h helpline study

Record of any Food Allergy Reactions

<table>
<thead>
<tr>
<th>Study Number__</th>
<th>Food</th>
<th>Symptoms</th>
<th>How long after eating?</th>
<th>What Treatment Given?</th>
<th>Did you attend doctor?</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
A 24-h helpline for access to expert management advice for food allergy-related anaphylaxis in children: protocol for a pragmatic randomised controlled trial

Maeve M Kelleher, Jonathan O'B Hourihane, Audrey DunnGalvin, Claire Cullinane, John Fitzsimons and Aziz Sheikh

BMJ Open 2012 2:
doi: 10.1136/bmjopen-2012-001282

Updated information and services can be found at:
http://bmjopen.bmj.com/content/2/4/e001282

These include:

References
This article cites 19 articles, 1 of which you can access for free at:
http://bmjopen.bmj.com/content/2/4/e001282#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Emergency medicine (276)
- Immunology (including allergy) (57)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/